# Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

> **NCT05644210** · — · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 80 (estimated)

## Conditions studied

- Antiphospholipid Syndrome

## Interventions

- **DRUG:** Telitacicept
- **DRUG:** Rituximab
- **DRUG:** Aspirin
- **DRUG:** Warfarin
- **DRUG:** Hydroxychloroquine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05644210
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644210, "Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05644210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*